Clinical Trials on Musculoskeletal Disorder of the Neck

Total 23694 results

Queensland Health
Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE)

Head and Neck Cancer | Cutaneous Squamous Cell Carcinoma of the Head and Neck

Australia
Oslo University Hospital
Asker & Baerum Hospital; University Hospital, Akershus

Completed

Conservative or Operative Treatment of Fractures in the Neck of the 5th Metacarpal Bone (MC-studien)

Fractures of the Neck

Norway
Centre Hospitalier Universitaire, Amiens

Recruiting

Nutritional Course of Care After Surgical Treatment at the Patients Affected by a Cancer of the Head and by the Neck (NUTRIMAX)

Head and Neck Cancer | Nutrition Disorders

France
University of Pittsburgh

Terminated

Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor

Squamous Cell Carcinoma of the Head and Neck | Primary Advanced Carcinoma of the Oral Cavity or Oropharynx

United States
Johns Hopkins University
Castle Biosciences Incorporated

Recruiting

Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck

Cutaneous Squamous Cell Carcinoma of the Head and Neck

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

United States, Korea, Republic of, Ukraine, United Kingdom
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.; Emory University; University of... and other collaborators

Terminated

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States
University Hospital, Ghent
Fund for Scientific Research, Flanders, Belgium

Completed

A Study of the Effect on Oro-dental Complications of Intensity Modulated Radiotherapy (IMRT) Versus Conventional Radiotherapy in Patients With Cancer of the Head or Neck

Cancer: Head or Neck

Belgium
Amgen
Merck Sharp & Dohme LLC

Completed

Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) (MASTERKEY232)

Carcinoma of the Head and Neck

United States, Canada, Switzerland, France, Spain, United Kingdom, Italy, Belgium, Austria, Australia, Greece
Nina Bhardwaj
Oncovir, Inc.

Terminated

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) (Hiltonol)

Melanoma | Breast Cancer | Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Skin | Sarcoma of the Skin | Basal Cell Cancer of the Skin

United States
Eben Rosenthal
National Cancer Institute (NCI)

Completed

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States
European Organisation for Research and Treatment...
Merck Sharp & Dohme LLC; Swiss Group for Clinical Cancer Research

Not yet recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer (PROLoNg)

Oligometastatic Squamous Cell Carcinoma of the Head and Neck
Kyunghee Burkitt, DO, PhD

Not yet recruiting

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC (HPV)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | HPV-Related Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx

United States
University of Chicago

Completed

Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) (DeCIDE)

Paranasal Sinus Neoplasms | Cancer of the Pharynx | Cancer of the Larynx | Cancer of the Nasal Cavity | Cancer of the Oral Cavity

United States, Spain, France, Croatia, Russian Federation
Maastricht University Medical Center

Recruiting

Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region

Quality of Life | Satisfaction, Patient | Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of Head and Neck | Skin Cancer | Squamous Cell Carcinomas | Squamous Cell Carcinoma of the Skin | Cutaneous Squamous Cell Carcinoma of the Head and Neck | Cutaneous Squamous Cell Carcinoma | High-Risk Cancer

Netherlands
National Cancer Institute (NCI)

Completed

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma... and other conditions

Canada
Sun Yat-sen University

Recruiting

Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

Squamous Cell Carcinoma Of The Head And Neck

China
Julie E. Bauman, MD, MPH
Bristol-Myers Squibb

Terminated

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Squamous Cell Carcinoma Of The Head And Neck

United States
University Hospital, Antwerp
Agentschap voor Innovatie door Wetenschap en Technologie

Completed

Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (ECLYPS)

Locally Advanced Squamous Cell Carcinoma of the Head and Neck Region

Belgium, Netherlands
Yale University
Boehringer Ingelheim; National Comprehensive Cancer Network

Recruiting

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Squamous Cell Cancers of the Head and Neck

United States
National Cancer Institute (NCI)

Completed

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Tongue Cancer | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Nasopharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Hoffmann-La Roche

Terminated

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
University of Texas Southwestern Medical Center

Terminated

Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck

Squamous Cell Carcinoma of the Head and Neck T1/2N0-2

United States
British Columbia Cancer Agency

Withdrawn

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Canada
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Study of a Simplified Geriatric Evaluation Performed by Oncologists Prior to Cancer Treatment by Radiotherapy or Chemotherapy in Subjects Aged 70 Years or Older With Inoperable Squamous Cell Cancer of the Head and Neck (ELAN-ONCOVAL)

Inoperable Squamous Cell Cancer of the Head and Neck

France
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...

United States
National Cancer Institute (NCI)

Completed

S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx and other conditions

United States
Novartis Pharmaceuticals

Completed

Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

Paget's Disease of the Bone

Spain, Canada, New Zealand, Belgium, South Africa, United Kingdom
EMD Serono

Completed

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck Cancer

Czech Republic, France, United Kingdom, Belgium, Hungary, United States, Poland, Slovakia
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue

Head and Neck Cancer

United States
Ohio State University Comprehensive Cancer Center
National Comprehensive Cancer Network

Completed

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
University of Michigan Rogel Cancer Center

Terminated

A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States
Pfizer

Completed

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine
Heath Skinner

Completed

SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

Squamous Cell Carcinoma of the Head and Neck Cancer | Previously-Irradiated

United States
Pfizer
EMD Serono; Astellas Pharma Inc; Nektar Therapeutics

Terminated

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)

Spain, United States, Poland, Belgium
National Taiwan University Hospital

Unknown

International Cancer of the Head and Neck, Genetics and Environment (InterCHANGE) Study (InterCHANGE)

Evaluate the Association Between Certain Environmental Exposures (e.g. Cigarette Smoking, Alcohol Drinking, Betel Nut Chewing…) and Head and Neck Cancers | Assess the Effect of Genetic Factors, Including Both SNP and Copy Number Variation (CNV) Through Analysis of Both Main Effect...

Taiwan
Nang Kuang Pharmaceutical Co., Ltd.

Terminated

Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer

Neoplasms, Head and Neck | Cancer of the Head and Neck

Taiwan
Mayo Clinic
Nova Southeastern University

Completed

Validity and Reliability of Outcome Measures in Patients With Cancer of the Head and Neck

Head and Neck Cancer

United States
Providence Health & Services

Active, not recruiting

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Cancer of the Head and Neck

United States
Sai-Hong Ignatius Ou
Sanofi

Terminated

Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer

Cancer of the Head and Neck

United States
Maastricht Radiation Oncology

Completed

PET With [18F]HX4 in Head and Neck Cancer

Cancer of the Head and Neck

Netherlands
AstraZeneca
MedImmune LLC

Active, not recruiting

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Spain, United States, Belgium, Germany, United Kingdom, Italy
University of Washington
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Nilam Ramsinghani

Withdrawn

Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer

Carcinoma of the Head and Neck
Memorial Sloan Kettering Cancer Center

Terminated

Improving End of Life Care in Head and Neck Cancer

The Families or Next of Kin of Patients Treated at MSKCC for Non-cutaneous Squamous Cell Carcinomas of the | Upper Aerodigestive Tract

United States
Gazi University

Completed

Validity and Reliability of the Turkish Version of WOOS

Evaluating the Validity and Reliability of the Turkish WOOS

Turkey

Clinical Trials on Musculoskeletal Disorder of the Neck

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations